About

Terremoto is a clinical-stage company breaking new ground in the targeted therapy landscape in oncology and genetic disease.

Our Mission

Delivering Medicines with Superior Therapeutic Benefit for Patients

We develop groundbreaking, best-in-class precision therapies to meet urgent patient needs. Through relentless science and deep purpose, we bring life-changing hope to those who need it most.

Enter covalent chemistry.

At Terremoto, we are breaking open the covalent drug universe with the power of lysine-targeted chemistry. In harnessing lysine-based covalency across the disease spectrum, we are focused on developing both best-in-class therapies against known drug targets and first-in-class medicines against the previously undruggable. Our founders helped create this emergent area of science, enabling our team of world-class chemists, biologists and drug developers to pursue a well-defined platform approach and translate treatments to patients as quickly as possible.

We view ourselves as champions for patients. The ultimate driving force behind our work is bringing highly effective medicines to people with devastating diseases as quickly as we possibly can.

The Earth-Shakers

Founded by the Pioneers

With a leadership team and advisory board bringing hundreds of collective years of experience in drug discovery, development, and global regulatory approval, we have the expertise to turn our ambitious vision into life-changing therapies.

Charles Baum, M.D., Ph.D.

Chief Executive Officer

James Christensen, Ph.D.

President, Head of Research & Development

Grace Lu

Chief Business Officer

Ronald Shazer, M.D., MBA

Senior Vice President, Head of Clinical Development

Cora Versaggi, SPHR

Senior Vice President, Human Resources

Solomon Reisberg, Ph.D.

Vice President, Head of Chemistry

Paul Stephensen

Vice President, Finance

Vivian Ho

Executive Director, Finance and Accounting

Maika Adair

Director, Clinical Supply Chain, Technical Operations

Noleen Bonfante

Executive Director, Clinical Operations

Jordan Carelli, Ph.D.

Director, Biology

Curtis Chin, M.D., Ph.D.

Executive Medical Director

Regina Choy, Ph.D.

Senior Director, Biology & Translational Sciences

Hamlet Chu, Ph.D.

Senior Director, Business Development

Hang Chu, Ph.D.

Executive Director, Medicinal Chemistry

Matthew Condakes, Ph.D.

Associate Director, Medicinal Chemistry

Michael Corbett, Ph.D.

Senior Director, Head of Technical Operations

Brittany Coyne

Senior Associate Scientist, Biology

Janaina Dargell

Associate Director, Human Resources

Subhamoy Das, Ph.D.

Senior Scientist 2, Biology

Mark Eskes

Senior Director, Project Management, Technical Operations

George Gindoyan

Executive Director, Information Technology and Informatics

Caroline Gundel

Research Operations Manager

Renee Himes

Associate Director, Clinical Operations

Victor Lee

Laboratory & Facilities Associate 2

Melvynn Lacoste

Scientist, Technical Operations

Nikhil Loka, Ph.D.

Director, Drug Product Development, Technical Operations

Romel Montellano, MBA

Executive Director, Regulatory Operations

Gigi Moore

Senior Executive Assistant/Office Manager

Johnson Nguyen

Senior Manager, Accounting Operations

Deborah Park

Scientist 2, Biology

Sarah Schisla

Associate Scientist, Technical Operations

Terri Schoeneman

Senior Director, Quality Assurance

Jacob Schrier, Ph.D.

Associate Director, Biology

Jane Shank

Business Manager/Senior Executive Assistant

Kathleen Shiffer, Ph.D.

Laboratory & Facilities Manager

Wagner Silva

Associate Director, Clinical Operations

Nicola Stagg, Ph.D., DABT

Executive Director, Head of Toxicology

Jessica Sun, Ph.D.

Executive Director, Head of In Vivo Pharmacology

Pranali Taskar

Scientist, Biology

Kin Yang, Ph.D.

Executive Director, Medicinal Chemistry

Adam Zajdlik

Senior Scientist, Medicinal Chemistry

Board of Directors

Charles Baum, M.D., Ph.D.

CEO, Terremoto

James Christensen, Ph.D.

President, Head of Research & Development, Terremoto

Reid Huber, Ph.D.

Partner, Third Rock Ventures

Daniel O’Connell, M.D., Ph.D.

Partner, Novo Holdings Venture Investments

Adam Schayowitz, Ph.D., MBA

Operating Partner, EcoR1 Capital

Peter Thompson, M.D.

Co-founder and Board Chairman, Terremoto
General Partner, OrbiMed

Founders

Scientific Advisors

Peter Thompson, M.D.

Co-founder and Board Chairman, Terremoto
General Partner, OrbiMed

Reid Huber, Ph.D.

Partner, Third Rock Ventures

Kevin Koch, Ph.D.

President, CEO and CFO, Edgewise
Venture Partner, OrbiMed

Jack Taunton, Ph.D.

Co-founder, Terremoto
Professor, Cellular Molecular
Pharmacology, UCSF

Matthew Jacobson, Ph.D.

Co-founder, Terremoto
Professor, Dept. of Pharmaceutical Chemistry, UCSF

John Link, Ph.D.

Former Vice President, Medicinal Chemistry, Gilead Sciences

Investors